Mankhwala omwe amagwiritsidwa ntchito pochiza myelofibrosis: Ruxolitinib

Myelofibrosis (MF) imatchedwa myelofibrosis.Komanso ndi matenda osowa kwambiri.Ndipo chomwe chimayambitsa matenda ake sichidziwika.Zizindikiro zodziwika bwino za matendawa ndi maselo ofiira a m'magazi achichepere ndi achichepere a granulocytic anemia okhala ndi kuchuluka kwa maselo ofiira ofiira a misozi.Kupuma kwa mafupa nthawi zambiri kumawonetsa kulakalaka kouma, ndipo ndulu nthawi zambiri imakulitsidwa mosiyanasiyana ndi matenda a osteosclerosis.
Primary myelofibrosis (PMF) ndi matenda a clonal myeloproliferative (MPD) a ma cell a hematopoietic stem cell.Chithandizo cha primary myelofibrosis chimathandiza makamaka, kuphatikizapo kuikidwa magazi.Hydroxyurea ikhoza kuperekedwa kwa thrombocytosis.Ochepa pachiwopsezo, odwala asymptomatic amatha kuwonedwa popanda chithandizo.
Maphunziro awiri amtundu wachitatu (STUDY1 ndi 2) anachitidwa kwa odwala omwe ali ndi MF (primary MF, post-geniculocytosis MF, kapena post-primary thrombocythemia MF).M'maphunziro onsewa, odwala omwe adalembetsa anali ndi splenomegaly yowoneka bwino pafupifupi 5 cm pansi pa nthiti ndipo anali ocheperako (2 prognostic factor) kapena pachiwopsezo chachikulu (3 kapena kupitilira apo) malinga ndi International Working Group consensus criteria (IWG).
Mlingo woyambirira wa ruxolitinib umachokera ku mapulateleti.15 mg kawiri pa tsiku kwa odwala omwe ali ndi mapulateleti owerengera pakati pa 100 ndi 200 x 10 ^ 9/L ndi 20 mg kawiri pa tsiku kwa odwala omwe ali ndi kupatsidwa zinthu za m'magazi kupitirira 200 x 10 ^ 9/L.
Mlingo wapayekha unaperekedwa molingana ndi kulolerana ndi mphamvu kwa odwala omwe ali ndi mapulateleti pakati pa 100 ndi 125 x 10 ^ 9/L, ndi mlingo waukulu wa 20 mg kawiri pa tsiku;kwa odwala omwe ali ndi mapulateleti pakati pa 75 ndi 100 x 10 ^ 9/L, 10 mg kawiri tsiku lililonse;ndi kwa odwala omwe ali ndi mapulateleti owerengera pakati pa 50 ndi ocheperapo kapena ofanana ndi 75 x 10 ^ 9 / L, 2 kawiri pa tsiku pa 5mg nthawi iliyonse.
Ruxolitinibndi oral JAK1 ndi JAK2 tyrosine kinase inhibitor yovomerezeka ku European Union mu August 2012 pofuna kuchiza myelofibrosis yapakati kapena yoopsa kwambiri, kuphatikizapo primary myelofibrosis, post-geniculocytosis myelofibrosis ndi post-primary thrombocythemia myelofibrosis.Pakadali pano, ruxolitinib Jakavi amavomerezedwa m'maiko opitilira 50 padziko lonse lapansi, kuphatikiza European Union, Canada ndi mayiko angapo aku Asia, Latin ndi South America.


Nthawi yotumiza: Jan-11-2022